Skip to content
Home/Companies/Biotech/BlueRock Therapeutics

BlueRock Therapeutics

Biotech·US·Exited 2019·Held 3yr
Entry
2016
Hold
3yr
Exit
2019

Who owns BlueRock Therapeutics?

BlueRock Therapeutics was owned by Leaps by Bayer through Leaps by Bayer (2015 vintage) from 2016 to 2019, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-03

Leaps by Bayer
Investor
Leaps by Bayer
Leaps by Bayer · 2015 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2019

More from Leaps by Bayer

Other portfolio companies in the same fund.

Celea Therapeutics
Celea Therapeutics
Active
BiotechUS· 2026
Leaf Agriculture
Active
ClimateTechUS· 2026
Sabanto
Active
AgTechUS· 2026
SonoThera
SonoThera
Active
BiotechUS· 2026
Souffle Therapeutics
Active
BiotechUS· 2025
WellTheory
WellTheory
Active
HealthTechUS· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Aldevron
Aldevron
Active
TA AssociatesUS
Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
Elkedonia
Elkedonia
Active
Capital Grand EstFrance
Track BlueRock Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy BlueRock Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on BlueRock Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue